Active	Status	Sponsor type	Region	Phase	Filter
2 Active 1 Inactive 3 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « April » « 2025 » M T W T F S S 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4   - « April » « 2025 » M T W T F S S 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4   Show only changed items Enrollment:

Advanced Filters

2 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Jacobs, Bradley
ReMEDy2, NCT05065216: Treatment of Acute Ischemic Stroke ( Trial)	Recruiting	2/3	728	Canada, US, RoW	Recombinant human tissue kallikrein, DM199, Placebo for DM199 Solution for Injection	DiaMedica Therapeutics Inc	Acute Stroke, Ischemic Stroke, Stroke	12/26	12/26
PURSUIT, NCT04720352: Prospective US Radiofrequency SUI Trial	Recruiting	N/A	390	US	Active treatment, Sham	Viveve Inc.	Urinary Incontinence, Stress	12/22	12/22

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Jacobs, Bradley
ReMEDy2, NCT05065216: Treatment of Acute Ischemic Stroke ( Trial)	Recruiting	2/3	728	Canada, US, RoW	Recombinant human tissue kallikrein, DM199, Placebo for DM199 Solution for Injection	DiaMedica Therapeutics Inc	Acute Stroke, Ischemic Stroke, Stroke	12/26	12/26
PURSUIT, NCT04720352: Prospective US Radiofrequency SUI Trial	Recruiting	N/A	390	US	Active treatment, Sham	Viveve Inc.	Urinary Incontinence, Stress	12/22	12/22